Filing Details

Accession Number:
0000899243-20-017602
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-24 21:19:40
Reporting Period:
2020-06-23
Accepted Time:
2020-06-24 21:19:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1538927 Forma Therapeutics Holdings Inc. FMTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1384859 Peter Kolchinsky C/O Ra Capital Management, L.p.
200 Berkeley Street, 18Th Floor
Boston MA 02116
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-06-23 5,011,651 $0.00 5,011,651 No 4 C Indirect See footnote
Common Stock Acquisiton 2020-06-23 4,000,000 $20.00 9,011,651 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series D Redeemable Convertible Preferred Stock Disposition 2020-06-23 21,437,376 $0.00 5,011,651 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. All series of preferred stock automatically converted into the Issuer's common stock on a one-for-4.2775 basis upon the closing of the Issuer's initial public offering on June 23, 2020 and had no expiration date.
  2. Includes (a) 3,216,720 shares held by RA Capital Healthcare Fund, L.P. (the "Fund"), (b) 1,252,913 shares held by RA Capital Nexus Fund, L.P. (the "Nexus Fund") and (c) 542,018 shares held by a separately managed account (the "Account").
  3. RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act").
  4. They disclaim beneficial ownership of any of the reported securities for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(1)(v) and (vii). The reporting person disclaims beneficial ownership of securities held by the Fund and the Nexus Fund for purposes of Rule 16a-1(a)(2), except to the extent of his pecuniary interest therein, and disclaims any pecuniary interest in securities held in the Account for purposes of Rule 16a-1(a)(2).
  5. The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the securities held in the Account.
  6. Includes 3,741,488 shares purchased by the Fund and 258,512 shares purchased by the Nexus Fund, in each case acquired in the Issuer's initial public offering on June 23, 2020 at a price of $20.00 per share pursuant to an underwritten public offering.
  7. Includes (a) 6,958,208 shares held by the Fund, (b) 1,511,425 shares held by the Nexus Fund and (c) 542,018 shares held by the Account.